These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31634398)

  • 1. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting.
    Garcia Garrido HM; Mak AMR; Wit FWNM; Wong GWM; Knol MJ; Vollaard A; Tanck MWT; Van Der Ende A; Grobusch MP; Goorhuis A
    Clin Infect Dis; 2020 Jun; 71(1):41-50. PubMed ID: 31634398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive Pneumococcal Disease Among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System.
    Marcus JL; Baxter R; Leyden WA; Muthulingam D; Yee A; Horberg MA; Klein DB; Towner WJ; Chao CR; Quesenberry CP; Silverberg MJ
    AIDS Patient Care STDS; 2016 Oct; 30(10):463-470. PubMed ID: 27749111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.
    Harboe ZB; Larsen MV; Ladelund S; Kronborg G; Konradsen HB; Gerstoft J; Larsen CS; Pedersen C; Pedersen G; Obel N; Benfield T
    Clin Infect Dis; 2014 Oct; 59(8):1168-76. PubMed ID: 25038114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for invasive pneumococcal disease in HIV-positive individuals in the era of highly active antiretroviral therapy.
    Sadlier C; O'Connell S; Kelleher M; Bergin C
    Int J STD AIDS; 2019 Apr; 30(5):472-478. PubMed ID: 30999829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).
    Meiring S; Cohen C; Quan V; de Gouveia L; Feldman C; Karstaedt A; Klugman KP; Madhi SA; Rabie H; Sriruttan C; von Gottberg A;
    PLoS One; 2016; 11(2):e0149104. PubMed ID: 26863135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study.
    Siemieniuk RA; Gregson DB; Gill MJ
    BMC Infect Dis; 2011 Nov; 11():314. PubMed ID: 22078162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumonia hospitalisation and case-fatality rates in older Australians with and without risk factors for pneumococcal disease: implications for vaccine policy.
    Dirmesropian S; Liu B; Wood JG; MacIntyre CR; McIntyre P; Karki S; Jayasinghe S; Newall AT
    Epidemiol Infect; 2019 Jan; 147():e118. PubMed ID: 30869015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
    Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
    Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, aetiology and serotype coverage for pneumococcal vaccines of community-acquired pneumonia in adults: a population-based prospective active surveillance study in Brazil.
    Duarte FG; Barberino MG; da Silva Moreira S; Reis JN; Spinardi JR; de Almeida RS; Allen KE; Alexander-Parrish R; Brim R; de Araújo Neto CA; Moreira ED
    BMJ Open; 2022 Apr; 12(4):e059824. PubMed ID: 35428648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
    BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting.
    Johnstone SL; Moore DP; Klugman KP; Madhi SA; Groome MJ
    Paediatr Int Child Health; 2020 Feb; 40(1):50-57. PubMed ID: 31156062
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era.
    Munier AL; de Lastours V; Porcher R; Donay JL; Pons JL; Molina JM
    Int J STD AIDS; 2014 Dec; 25(14):1022-8. PubMed ID: 24676129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009-2014.
    Chowers M; Regev-Yochay G; Mor O; Cohen-Poradosu R; Riesenberg K; Zimhony O; Chemtob D; Stein M; Dagan R; Levy I
    Hum Vaccin Immunother; 2017 Jan; 13(1):216-219. PubMed ID: 27648488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay.
    LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk WHB; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    Vaccine; 2022 Apr; 40(18):2635-2646. PubMed ID: 35315326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines.
    Heo JY; Seo YB; Jeong HW; Choi MJ; Min KH; Choi WS; Lee J; Noh JY; Cheong HJ; Kim WJ; Song JY
    Vaccine; 2020 Nov; 38(49):7747-7755. PubMed ID: 33164798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.
    Weycker D; Farkouh RA; Strutton DR; Edelsberg J; Shea KM; Pelton SI
    BMC Health Serv Res; 2016 May; 16():182. PubMed ID: 27177430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006.
    Steenhoff AP; Wood SM; Rutstein RM; Wahl A; McGowan KL; Shah SS
    Pediatr Infect Dis J; 2008 Oct; 27(10):886-91. PubMed ID: 18776825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children.
    Burgos J; Peñaranda M; Payeras A; Villoslada A; Curran A; Garau M; Riera M; Crespo M; Navarro J; Van den Eynde E; Planes AM; Ribera E; Pahissa A; Falcó V
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):31-8. PubMed ID: 22156821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.